ASSIGNMENT AGREEMENT

EX-10.7 2 v451545_ex10-7.htm EXHIBIT 10.7

 

Exhibit 10.7

 

ASSIGNMENT AGREEMENT

 

This Assignment Agreement (the “Agreement”) is made as of March 15, 2016 (the “Effective Date”), by and between Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Tallikut”), and Accelerated Pharma, Inc., a corporation organized under the laws of Delaware (“API”).

 

RECITALS

 

WHEREAS, Tallikut owns the right, title and interest in and to all assets related to picoplatin including licensed rights to the AnorMED patents (the “Picoplatin Assets”); and

 

WHEREAS API is desirous of acquiring the entire right, title and interest in the same.

 

NOW, THEREFORE, in consideration of the above recitals and the mutual covenants hereinafter set forth, API and Tallikut, intending to be legally bound, hereby agree as follows:

 

1.Assignment. Tallikut agrees to sell, assign, transfer and convey to API all of Tallikut’s right, title and interest in and to all of the following (collectively, the “Property Rights”):

 

1.1. the worldwide rights, title and interest in and to any and all trade names, trademark rights, trademarks and service marks (including any and all registrations, licenses, applications and common law marks pertaining thereto), used in connection with the Picoplatin Assets, together with (a) the goodwill of the Picoplatin Assets associated therewith and symbolized by same and (b) all common law rights therein and the right to sue for past infringement of any and all of said trademarks (collectively, the “Trademarks”);

 

1.2. all worldwide rights, title and interest of Tallikut in and to the designs, processes, drawings, schematics, copyrights and copyright applications, if any, inventions, processes, know-how, trade secrets, patents (including any and all letter patents) patent applications (including any Patent Cooperation Treaty patent applications and corresponding National patent applications) and other proprietary information related to the Picoplatin Assets, including, without limitation, any registered copyrights, patents and copyright and patent applications identified on Exhibit E, and in and to all substitutions, divisions, continuations, continuationsin-part, reexaminations, extensions, renewals and reissues (as applicable) thereof, and including without limitation of generality, all rights of priority resulting from the filing of patent applications relating to any of the foregoing as well as any and all choses in action and any and all claims and demands, both at law and in equity, that Tallikut has or may have for damages or profits accrued or to accrue on account of the infringement of any patents, patent applications, letter patents, inventions, improvements and discoveries (or any provisional rights therein), the same to be held and enjoyed by API, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Tallikut if the assignment set forth herein had not occurred, the full and complete right to file patent applications on the aforesaid inventions, improvements, discoveries and applications in all countries of the world and the entire right, title and interest in and to any letter patent which may issue thereon in the United States or in any country, and any and all renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same (collectively, the “Intellectual Property Rights”);

 

   

 

 

1.3. all files, lists, publications, and other records and data of Tallikut used in or relating to the Picoplatin Assets, regardless of the medium on which such information is stored and maintained; and

 

1.4. all rights in and to any governmental and private permits, licenses, and authorizations, to the extent assignable, used in or relating to the Picoplatin Assets.

 

2.    Title Passage. Upon the Effective Date, title to all of the Property Rights shall pass to API. Tallikut shall, upon API’s request, execute any assignments, conveyances and/or bills of sale required to assign, transfer, set over, convey, assure and confirm unto and vest in API, its successors and assigns, title to all of the Property Rights, as well as such other instruments of conveyance as counsel for API may reasonably deem necessary to effect or evidence the transfers contemplated hereby.

 

3.    Purchase Price. The aggregate consideration for the sale, transfer, conveyance and assignment of all the Property Rights to API shall be $1 (the “Purchase Price”), receipt of which is hereby acknowledged.

 

 2 

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Assignment Agreement on the dates indicated below.

 

TALLIKUT PHARMACEUTICALS, INC.   ACCELERATED PHARMA, INC.
     
By /s/ Fred Craves   By: /s/ Michael Fonstein
         
Name:   Fred Craves   Name: Michael Fonstein
         
Title:   Chairman of the Board   Title:   Chief Executive Officer
         
Date: 3/15/16   Date: 3/15/16

 

State of _________________________________

County of________________________________

 

ACKNOWLEDGMENT

 

On this________ day of March, in the year 2016, before me, the undersigned, personally appeared Fred Craves, the Chairman of the Board of Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed the within Assignment Agreement in his or her capacity behalf of said corporation and acknowledged to me that he or she executed the same for the purposes therein stated.

 

Seal:

 

Notary Public____________________________

My commission expires:

 

[SIGNATURE PAGE TO ASSIGNMENT AGREEMENT]

 

 3 

 

 

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

 

 

State of California
 
County of   San Francisco                                                   

 

On 3/15/16   before me, M. A. Josephson
  Date   Here Insert Name and Title of the Officer

 

Personally appeared /s/ Fred Craves
  Name(s) of Signer(s)
   
   

 

  who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.
 
I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.
   
  WITNESS my hand and official seal.
   
  Signature /s/ M. A. Josephson
Place Notary Seal above   Signature of Notary Public

 

OPTIONAL

 

Though the information below is not required by law, it may prove valuable to persons relying on the document
and could prevent fraudulent removal and reattachment of this form to another document.

 

Description of Attached Document

 

Title or Type of Document:  

 

Document Date:   Number of Pages:  

 

Signer(s) Other Than Named Above:  

 

Capacity(ies) Claimed by Signer(s

 

Signer’s Name: ______________________     Signer’s Name: _________________________
¨ Individual     ¨ Individual
¨ Corporate Officer — Title(s): ________     ¨ Corporate Officer — Title(s): ____________
¨ Partner — ¨ Limited ¨ General     ¨ Partner — ¨ Limited ¨ General
¨ Attorney in Fact     ¨ Attorney in Fact  
¨ Trustee ¨ Trustee
¨ Guardian or Conservator ¨ Guardian or Conservator
¨ Other: _______________________ ¨ Other: ____________________
_______________________________ ____________________________
Signer Is Representing: ____________ Signer Is Representing: _________
______________________________ ____________________________
______________________________ ____________________________

 

 

 

©2007 National Notary Association• 9350 De Solo Ave., P.O. Box 2402 *Chatsworth. CA ###-###-#### • www NationalNotary.org Item #5907 Reorder:Call Toll-Free ###-###-####

 

 4 

 

 

EXHIBIT E

 

Intellectual Property Rights

 

        Application No.
or Registration
No.
  Application Filing
Date or Registration
Patent   Country   as applicable)   Date (as applicable)
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER   US   60/857,067   11/6/2006
             
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER   US   60/877,515   12/28/2006
             
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER   US   60/927,347   5/3/2007
             
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER   US   60/931,309   5/22/2007
             
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER   US   60/969,441   8/31/2007
             
USE OF PICOPLATTN TO TREAT SMALL CELL LUNG CANCER   US   12/508,392   7/23/2009
             
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER   US   60/857,017   11/6/2006
             
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER   US   60/857,564   11/8/2006
             
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER   US   60/877,570   12/28/2006
             
USE OF PICOPLATTN TO TREAT PROSTATE CANCER   US   60/889,179   2/9/2007

 

 5 

 

 

        Application No.    
        or Registration   Application Filing
        No.   Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   US   60/890,950   2/21/2007
             
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   US   60/931,609   5/24/2007
             
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   US   60/952,440   7/27/2007
             
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   US   11/935,979   11/6/2007
             
A METHOD OF TREATMENT OF COLORECTAL CANCER   US   60/857,066   11/6/2006
             
A METHOD OF TREATMENT OF COLORECTAL CANCER   US   60/857/725   11/8/2006
             
A METHOD OF TREATMENT OF COLORECTAL CANCER   US   60/877,495   12/28/2006
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   60/889,191   2/9/2007
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   60/931,589   5/24/2007
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   60/683,852   10/30/2007
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   12/367,394   2/6/2009

 

 6 

 

 

        Application No.    
        or Registration   Application Filing
        No.   Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   121464,662   5/12/2009
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   121465,563   5/13/2009
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   12/508,372   7/23/2009
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   PCT   PCT/U52010/34593   5/12/2010
             
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER   US   13/319,852   11/10/2011
             
ENCAPSULATED PICOPLATIN   US   60/889,201   2/912007
             
ENCAPSULATED PICOPLATIN   US   60/889,675   2/13/2007
             
ENCAPSULATED PICOPLAT1N   US   60/984,156   10/31/2007
             
ENCAPSULATED PICOPLATIN   US   60/989,020   11/19/2007
             
ENCAPSULATED PICOPLATIN   PCT   PCT/U52008/00174 6   2/8/2009
             
ENCAPSULATED PICOPLATIN   US   12/536,311   8/5/2009

 

 7 

 

 

        Application No.
or Registration
No.
  Application Filing
Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
ENCAPSULATED PICOPLATIN   AU   2008214199   2/8/2008
             
ENCAPSULATED PICOPLATIN   BR   PI 0806362-1   2/8/2008
             
ENCAPSULATED PICOPLATIN   CA   2,677,639   2/8/2008
             
ENCAPSULATED PICOPLATIN   CN   200880011347.9   2/8/2008
             
ENCAPSULATED PICOPLAHN   EG   1200/2009   2/8/2008
             
ENCAPSULATED PICOPLAHN   EP   08725387.8   2/8/2008
             
ENCAPSULATED PICOPLATIN       10102719.4   2/8/2008
             
ENCAPSULATED PICOPLATIN   ID   W-00200902208   2/8/2008
             
ENCAPSULATED PICOPLATIN   IL   200261   2/8/2008
             
ENCAPSULATED PICOPLATIN   N   5257/CHENP/2009   2/8/2008
             
ENCAPSULATED PICOPLATIN   JP   2009-549126   2/8/2008
             
ENCAPSULATED PICOPLATIN   KR   10 ###-###-####   2/8/2008
             
ENCAPSULATED PICOPLATIN   MX   MX/s/2009/008487   2/8/2008
             
ENCAPSULATED PICOPLATIN   PH   1-2009-501520   2/8/2008
             
ENCAPSULATED PICOPLATIN   RU   2009133447   2/8/2008
             
ENCAPSULATED PICOPLATIN   UA   200909261   2/8/2008

 

 8 

 

 

        Application No.    
        or Registration   Application Filing
        No.   Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
ENCAPSULATED PICOPLATIN   VN   1-2009-01904   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORMS   US   60/889,171   2/9/2007
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   US   60/889,681   2/13/2007
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   PCT   PCT/US2008/00175 2   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   US   12/536,335   8/5/2009
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   AU   2008214202   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   BR   0806418-0   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   CA   2,677,640   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   CN   200880011357.2   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   EG   1201/2009   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   EP   08725393.6   2/8/2008

 

 9 

 

 

        Application No.    
        or Registration   Application Filing
        No.   Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   HK   10106157.4   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   ID   W-00200902207   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   IL   200262   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   IN   5256/CHENP/2009   2/8/2008
             
STABILIZED PICOPLAT1N ORAL DOSAGE FORM*   JP   2009-549128   2/8/2008
             
STABILIZED PICOPLAT1N ORAL DOSAGE FORM*   KR   10 ###-###-####   2/8/208
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   MX   MX/a/2009/008488   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   PH   1-2009-501521   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   RU   2009133446   2/8/2008
             
STABILIZED PICOPLATIN ORAL DOSAGE FORM*   UA   200909262   2/8/2008
             
STABILIZED PICOPLAT1N ORAL DOSAGE FORM AND   VN   1-2009-01903   2/8/2008

 

 10 

 

 

Patent   Country  

Application No.
or Registration
No.

(as applicable)

  Application Filing
Date or Registration
Date (as applicable)
PROCESS FOR  PREPARING THE  SAME*            
             
STABILIZED INTRAVENOUS DOSAGE FORM   US   60/949,639   6/27/2007
             
ORAL FORMULATION FOR PICOPLATIN   US   60/950,033   7/16/2007
             
ORAL FORMULATION FOR PICOPLAT1N   US   61/043,962   4/10/2008
             
ORAL FORMULATION FOR PICOPLATIN   PCT   PCT/U S2008/008669   7/16/2008
             
ORAL FORMULATION FOR PICOPLATIN   US   12/669,274   1/15/2010
             
ORAL FORMULATION FOR PICOPLAT1N   CA   2,693,057   7/16/2008
             
ORAL FORMULATION FOR PICOPLAT1N   CN   200880103323.6   7/16/2008
             
ORAL FORMULATION FOR PICOPLATIN   EP   08780206.2   7/16/2008
             
ORAL FORMULATION FOR PICOPLATIN   I-1K   11101572.1   7/16/2008
             
ORAL FORMULATION FOR PICOPLATIN   .1P   2010-517010   7/16/2008
             
ORAL FORMULATION FOR PICOPLATIN   TW   097127053   7/16/2008
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   US   61/027,387   2/8/2008

 

 11 

 

 

Patent   Country  

Application No.
or Registration
No.

(as applicable)

  Application Filing
Date or Registration
Date (as applicable)
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   PCT   PCT/U52009/00077 0   2/6/2009
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   US   12/866,702   11/11/2010
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   AU   2009210654   2/6/2009
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   CA   2,715,348   2/6/2009
             
USE OF PICOPLATIN AND 13EVACIZUMAB TO TREAT COLORECTAL CANCER   UN   200980109758.6   2/6/2009
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   EP   09708527.8   2/6/2009
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   HK   11109428.0   2/6/2009
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   JP   2010-545883   2/6/2009

 

 12 

 

 

Patent   Country   Application No.
or Registration
No.
(as applicable)
  Application Filing
Date or Registration
Date (as applicable)
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   US   61/027,382   2/8/2008
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   PCT   PCT/US2009/00077 3   2/6/2009
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   US   12/866,706   11/15/2010
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   AU   2009210656   2/6/2009
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   CA   2,715,353   2/6/2009
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   CN   200980111015.2   2/6/2009
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   EP   097083873   2/6/2009
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   HK   111094253   2/6/2009
             
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER   JP   2010-545885   2/6/2009
             
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER   US   61/027,360   2/8/2008

 

 13 

 

 

        Application No.    
        or Registration   Application Filing
        No.   Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER   PCT   PCT/US2009/00075 0   2/6/2009
             
PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER   US   12/866,710   11/10/2010
             
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER   AU   2009210734   2/6/2009
             
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER   CA   2,715,329   2/6/2009
             
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER   CN   200980110139.9   2/6/2009
             
PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER   EP   09708292.9   2/6/2009
             
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER   HK   11109534J   2/6/2009
             
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER   JP   2010-545878   2/6/2009
             
COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM   US   61/027,388   2/8/2008
             
COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM   US   61/055/071   5/21/2008

 

 14 

 

 

Patent   Country  

Application No.
or Registration
No.
(as applicable)

  Application Filing
Date or Registration
Date (as applicable)
STABILIZED PICOPLATIN DOSAGE FORM   PCT   PCT/U52008/08076   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   US   12/635,517   12/10/2009
             
COMBINATION THERAPY FOR OVARIAN CANCER   US   12/635,534   12/10/2009
             
COMBINATION THERAPY FOR OVARIAN CANCER   US   12/781,599   5/17/2010
             
COMBINATION THERAPY FOR OVARIAN CANCER   PCT   PCT/US11/036855   5/17/2011
             
STABILIZED PICOPLATIN DOSAGE FORM   AU   2008295576   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   BR   P10811816-7   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   CA   2,691,115   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   CN   200880022248.0   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   EP   08828991.3   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   HK   10108170.3   6/27/2008

 

 15 

 

 

        Application No.
or Registration
No.
  Application Filing
Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
STABILIZED PICOPLATIN DOSAGE FORM   ID   W-00201000277   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   ru       6/27/208
             
STABILIZED PICOPLATIN DOSAGE FORM   IN   7725/CHENP/2009   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   JP   20 10-5 14837   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   KR   10 ###-###-####   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   MX   MX/a12009/013835   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   RU   2010102096   6/27/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   TW   097124033   6/28/2008
             
STABILIZED PICOPLATIN DOSAGE FORM   UA   201000817   6/28/2008
             
PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY   US   61/169,679   4/15/2009
             
PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY   US   61/170,487   4/17/2009
             
HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY   PCT   PCT/U52010/00735   3/11/2010

 

 16 

 

 

        Application No.    
        or Registration   Application Filing
        No.   Date or Registration
Patent   Country   (as applicable)   Date (as applicable)
HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY   US   13/264,343   10/13/2011
             
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   US   61/177,567   5/12/2009
             
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   PCT   PCT/U52010/34591   5/12/2010
             
USE OF PICOPLATIN TO TREAT PROSTATE CANCER   US   13/319,647   11/9/2011
             
USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER   US   61/177,571   5/12/2009
             
IMPROVED SYNTHESIS OF PICOPLATIN   US   61/186,526   6/12/2009
             
IMPROVED SYNTHESIS OF PICOPLATIN   PCT   PCT/US2010/38348   6/11/2010
             
IMPROVED SYNTHESIS OF PICOPLATIN   TW   099119171   6/11/2010
             
METHOD TO TREAT SMALL CELL LUNG CANCER   US   61/311,169   3/5/2010
             
METHOD TO TREAT SMALL CELL LUNG CANCER   US   61/345,442   5/17/2010
             
METHOD TO TREAT SMALL CELL LUNG CANCER   PCT   PCT/U52011/02726 4   3/4/2011

 

 17 

 

 

Patent   Country  

Application No.
or Registration
No,
(as applicable)

  Application Filing
Date or Registration
Date (as applicable)
METHOD TO TREAT SMALL CELL LUNG CANCER   TW   100 1076 12   3/7/2011
             
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER   US   61/345,451   5/17/2010
             
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER   US   61/346,777   5/20/2010
             
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER   PCT   PCT/1J52011/02726   3/4/2011
             
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER   TW   100107621   3/7/2011
             
INHIBITORS OF FOCAL ADHESION KINASE   PCT   PCT/1J52008/00320   3110/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   US   12/531,010   9/11/2009
             
INHIBITORS OF FOCAL ADHESION KINASE   CA   2,681,015   3/10/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   CN   200880015910.X   3/10/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   EP   08726698.7   3/10/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   HK   10107956.5   3/10/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   IN   5948/DELNP/2009   3/10/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   JP   2009-553600   3/10/2008
             
INHIBITORS OF FOCAL ADHESION KINASE   TW   97109125   3/14/2008

 

 18 

 

 

Patent   Country  

Application No.
or Registration
No.
(as applicable)

  Application Filing
Date or Registration
Date (as applicable)
METHODS OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS   PCT   PCT/US2010/04535   8/12/2010
             
SYNTHESIS AND USE OF KINASE INHIBITORS   US   61/359,942   6/30/2010
             
SYNTHESIS AND USE OF KINASE INHIBITORS   PCT   PCT/US2011/04216   6/28/2011
             
ORAL FORMULATION OF 1UNASE INHIBITORS   US   61/359,694   6/29/2010
             
ORAL FORMULATION OF KINASE INHIBITORS   PCT   PCT/U52011/04216   6/28/2011

 

 19